Femara Benefits Younger Women With Breast Cancer
Most Women May Not Need Additional Treatment
WebMD News Archive
Femara Slashes Estrogen Levels continued...
That's where Femara and other aromatase inhibitors come in. Aromatase inhibitors lower the levels of circulating estrogens in the body. They inhibit the aromatase enzyme that produces estrogen.
The new study included 471 women who had a history of invasive breast cancer but no signs of breast cancer after five years of tamoxifen treatment. All had been treated with surgery and radiation before receiving tamoxifen alone or chemotherapy and tamoxifen. None was given an aromatase inhibitor.
By an average of eight years later, cancer came back in 26 women, and 10 other women developed tumors in their originally unaffected breasts. With these numbers, the researchers say that patients with higher risk for recurrence, particularly due to young age or lymph node involvement, would have the greater benefit from the addition of Femara.